Prof Dr Lim Kah Meng
Dr Lim Kah Meng has dedicated a large part of his research focus on molecular biomedicine and for more than 20 years, he has fervently pursued his scientific interests on bioactive molecules that govern and regulate cellular pathways leading to cellular homeostasis and wellbeing. He has been credited as the ‘Father of Molecular Edible Bird Nests’. He has filed more than 29 patents on the extraction processes for the bioactive molecules including immunological active biomolecules from edible bird nests.
Dr Lim is also known in this region to be the “Father of Molecular Placenta’ where he has successfully developed highly popular products for the commercial world based on placental stem cell extracts. He has since diversified into stem cell research including products or platforms based on induced pluripotent stem cells for personalized aesthetics and therapeutics for acute illnesses such as diabetes, psoriasis and dementia.
Dr Lim has also published a paper documenting successful clinical cases for 9 cancer patients in Singapore using high dose intravenous vitamin C. Dr Lim is also deep into biomedical research for neuroscience. He has filed for at least 5 patents related to cannabinoids, specifically on medical cannabis but not exclusive to just neurological functions, optimising bioactive compounds.
Dr Lim’s most recent research is in successfully using micro RNAs as the next generation diagnostic markers for most cancers and chronic diseases detection. Commercially, he has successfully developed and invested in at least 7 potentially unicorn start-up companies and as an accomplished scientist and established business leader, he was also the recipient for the Singapore award of the 10 outstanding young persons of the world in 2012.
Dr Lim joined the Singapore Paincare Holdings Ltd as an Independent Non-executive Director in March 2021 and at the same time, serves as an Honorary Advisor of the World LIN Chamber of Commerce, Singapore.